<DOC>
	<DOCNO>NCT01063517</DOCNO>
	<brief_summary>To assess efficacy olaparib give combination paclitaxel compare paclitaxel alone define progression-free survival ( PFS ) , patient recurrent metastatic gastric cancer progress follow first-line therapy</brief_summary>
	<brief_title>Efficacy Study Olaparib With Paclitaxel Versus Paclitaxel Gastric Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Recurrent metastatic gastric cancer progress follow first linetherapy Confirmed ATM protein status IHC archival tumour sample At least one lesion ( measurable and/or nonmeasurable ) accurately assess imaging ( CT/MRI ) baseline follow visit More one prior chemotherapy regimen treatment gastric cancer metastatic recurrent set Any previous treatment PARP inhibitor , include olaparib Patients second primary cancer , except ; adequately treat non melanoma skin cancer , curatively treated situ cancer cervix , solid tumour curatively treat evidence disease &gt; 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Poly ( ADP ribose )</keyword>
	<keyword>polymerase ( PARP )</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>olaparib</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>ATM AZD2281</keyword>
	<keyword>Ku0059436</keyword>
	<keyword>Homologous Recombination deficiency ( HRD )</keyword>
	<keyword>Recurrent gastric cancer</keyword>
	<keyword>metastatic gastric cancer</keyword>
</DOC>